Schering-Plough Receives EU Approval for HCV Combination Therapy
Posted on: Friday, 16 November 2007, 12:00 CST
The European Commission has approved Schering-Plough's 48-week standard-dose Pegintron and Rebetol combination therapy for retreating adult patients with chronic hepatitis C who have failed a prior treatment.
The approval is based on results from an ongoing non-comparative clinical study (EPIC3) in which 1,336 patients with moderate to severe fibrosis or cirrhosis who failed previous treatment with combination alpha interferon/ribavirin therapy were retreated with Pegintron combination therapy.
In this study, virological response at week 12 of treatment was shown to be an important predictor for achieving a sustained virological response (SVR), with 57% of patients who had undetectable virus (HCV- RNA) at week 12 going on to achieve SVR with a 48-week course of therapy. Within this subgroup, the SVR rates were 59% and 47% for patients who failed prior therapy with non-pegylated or pegylated interferon, respectively.
Overall, 23% of patients in the study achieved SVR, including 16% of patients who failed prior peginterferon and ribavirin combination therapy. Based on results from the EPIC3 study, the recommended duration of dosing with Pegintron combination therapy for retreating patients who failed previous therapy and who have undetectable virus at week 12 is 48 weeks, regardless of HCV genotype.
Pegintron and Rebetol is the first and only pegylated interferon combination therapy approved in the EU for retreating both hepatitis C (HCV)relapsers and nonresponders. The European Commission approval of this expanded indication for Pegintron and Rebetol results in marketing authorization with unified labeling that is valid in the current EU 27 member states as well as in Iceland and Norway.
Source: Datamonitor
Related Articles
- InteKrin Therapeutics Announces Enrollment Completion of 360 Patient, 24 week Phase 2b Study
- Schering-Plough Completes Enrollment of Boceprevir Registration Studies in Treatment-Naive and Treatment-Experienced HCV Patients
- Breast Cancer Patients Take DNA Test to Determine Best Treatment
- XTL Completes Patient Randomization in Phase IIb Study of Diabetic Pain Drug
- Omeros Announces Initiation of Patient Enrollment in OMS201 Phase 1 Study
- Telaprevir-Based PROVE Studies Show Significantly Higher SVR Rates in Treatment-Naive Genotype 1 Hepatitis C Patients in Half the Time of Current Treatments
- Technological Advances in Radiation Therapy and Minimally Invasive Surgery Will Shape Future Treatment Choices for Prostate Cancer
- NRC+Picker Highlights Safe Medication Administration During National Patient Safety Week
- Vicriviroc Demonstrates Potent and Sustained Viral Suppression in ACTG Phase II Clinical Study in Treatment-Experienced HIV Patients
- Javelin Treats First Patient in Phase III Pain Study
 |
 |
User Comments (0)
RSS Feeds